Evestia Clinical and Atlantic Research Group merge to create global specialist CRO
Ella Day | July 23, 2025 | News story | Clinical Trial Services, Mergers and Acquisitions, Research and Development | Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation
UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) specialising in high-growth therapeutic areas. Backed by private equity firm Kester Capital, the move marks a significant step in Evestia’s strategy to grow globally through targeted acquisitions and service expansion.
The merger more than doubles the size of the ARG and extends Evestia Clinical’s operations across the US, while broadening its therapeutic reach to include neurology and late-stage clinical trial services. This adds to its existing specialisms in oncology, rare diseases, immunology and inflammation.
“We’re incredibly excited to be joining forces with ARG as we accelerate our journey to build Evestia Clinical into a leading mid-tier specialist CRO with a truly global reach,” said Lewis Cameron, CEO of Evestia Clinical.
ARG brings additional technological capabilities and therapeutic expertise. Its clients will gain immediate access to Evestia’s wider platform, particularly in rare disease research. ARG’s CEO Paul Bishop and president Lyle Camblos will join Evestia’s senior leadership team, with all staff expected to transition as part of the agreement.
“ARG has found the ideal and trusted partner for our next stage of growth,” said Bishop and Camblos in a joint statement. “This merger offers our clients continuity and access to broader capabilities worldwide.”
The merged company will operate under the Evestia Clinical brand with dual headquarters in Letchworth, UK, and Charlottesville, US, serving clients across the clinical trial lifecycle.
Ella Day
23/7/25
Related Content
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended …
PharmNovo submits CTA for non-addictive neuropathic pain therapeutic
Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities …
Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, …
